Aims: Previous studies have shown that membranous expression of podocalyxin-like protein (PODXL) is associated with poor prognosis in colorectal cancer (CRC). In this study, we compared PODXL expression in primary CRC and synchronous lymph node metastases. We further analyzed whether its expression changed in rectal tumours after neoadjuvant radiation therapy. Methods and results: The studied cohort consists of 73 consecutive patients from the South-Swedish Colorectal Cancer Biobank. Immunohistochemical PODXL expression was examined on full-face sections from all primary tumours and all 140 available lymph node metastases from 31 cases. Membranous PODXL expression was denoted in 18/73 (24,7%) primary tumours, with a high concordance between...
The primary cause of colorectal cancer (CRC) recurrence is increased distant metastasis after radiot...
Metastatic disease is the leading cause of cancer mortality. Identifying biomarkers and regulatory m...
The molecular heterogeneity of breast cancers makes them very challenging to diagnose and treat. Whi...
Colorectal cancer (CRC) is the third most common cancer worldwide with more than 700,000 deaths ever...
Background: Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein and stem cell marker that has...
Background: Podocalyxin-like protein (PODXL) is a cell surface transmembrane glycoprotein, the expre...
Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein associated with aggressive tumor phenotyp...
Abstract Background We have previously shown that podocalyxin-like protein (PODXL) is a prognostic b...
Background: Podocalyxin-like 1 (PODXL) is an anti-adhesive transmembrane protein that has been demon...
Colon cancer is the third most common cancer in the world and the second most common cause of cancer...
Podocalyxin (PODXL), a glycosylated cell surface sialomucin of the CD34 family, is normally expresse...
The outcome of periampullary adenocarcinomas remains poor with few treatment options. Podocalyxin-li...
The advent of targeted therapies has vastly improved cancer diagnostics and treatments over the last...
Oral cancers constitute approximately 2% of all cancers, with the most common histological type bein...
Lymphatic invasion (LVI), the presence of tumour emboli within the peritumoural lymphatics of the br...
The primary cause of colorectal cancer (CRC) recurrence is increased distant metastasis after radiot...
Metastatic disease is the leading cause of cancer mortality. Identifying biomarkers and regulatory m...
The molecular heterogeneity of breast cancers makes them very challenging to diagnose and treat. Whi...
Colorectal cancer (CRC) is the third most common cancer worldwide with more than 700,000 deaths ever...
Background: Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein and stem cell marker that has...
Background: Podocalyxin-like protein (PODXL) is a cell surface transmembrane glycoprotein, the expre...
Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein associated with aggressive tumor phenotyp...
Abstract Background We have previously shown that podocalyxin-like protein (PODXL) is a prognostic b...
Background: Podocalyxin-like 1 (PODXL) is an anti-adhesive transmembrane protein that has been demon...
Colon cancer is the third most common cancer in the world and the second most common cause of cancer...
Podocalyxin (PODXL), a glycosylated cell surface sialomucin of the CD34 family, is normally expresse...
The outcome of periampullary adenocarcinomas remains poor with few treatment options. Podocalyxin-li...
The advent of targeted therapies has vastly improved cancer diagnostics and treatments over the last...
Oral cancers constitute approximately 2% of all cancers, with the most common histological type bein...
Lymphatic invasion (LVI), the presence of tumour emboli within the peritumoural lymphatics of the br...
The primary cause of colorectal cancer (CRC) recurrence is increased distant metastasis after radiot...
Metastatic disease is the leading cause of cancer mortality. Identifying biomarkers and regulatory m...
The molecular heterogeneity of breast cancers makes them very challenging to diagnose and treat. Whi...